Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Cervantes F, Hernández-Boluda JC, Odriozola J, Camós M, Villalón L, Martínez-Climent JA, del Campo R, García-Conde J, Montserrat E. Cervantes F, et al. Among authors: villalon l. Br J Haematol. 2003 Feb;120(3):500-4. doi: 10.1046/j.1365-2141.2003.04077.x. Br J Haematol. 2003. PMID: 12580969 Free article. Clinical Trial.
Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
López-Jiménez J, Pérez-Oteyza J, Munoz A, Parra C, Villalón L, Ramos P, Maldonado M, García-Laraña J, Otheo E, Roldán E, García-Avello A, Odriozola J. López-Jiménez J, et al. Among authors: villalon l. Bone Marrow Transplant. 1997 Mar;19(5):429-34. doi: 10.1038/sj.bmt.1700693. Bone Marrow Transplant. 1997. PMID: 9052907 Clinical Trial.
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J. Cervantes F, et al. Among authors: villalon l. Haematologica. 2003 Oct;88(10):1117-22. Haematologica. 2003. PMID: 14555307 Clinical Trial.
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
Luna A, Pérez-Lamas L, Boque C, Giraldo P, Xicoy B, Ruiz Nuño C, Vega MM, Alvarez-Larrán A, Salamanca A, García-Noblejas A, Vall-Llovera F, Villalon L, De Las Heras N, Ramila E, Pérez-Encinas M, Cuevas B, Perez-Lopez R, Sanchez-Guijo F, Jiménez-Velasco A, Lakhwani S, Casado LF, Rosell A, Escola A, Fernández MJ, Garcia-Hernandez C, Cervero C, Mora E, Sagüés M, Suarez-Varela S, Vélez P, Carrascosa Mastell P, Bitaube RF, Serrano L, Cortes M, Vera Goñi JA, Steegmann JL, de Soria VGG, Alonso-Dominguez JM, Araujo MC, Coll AP, Hernandez-Boluda JC, García-Gutiérrez V. Luna A, et al. Among authors: villalon l. Ann Hematol. 2022 Oct;101(10):2263-2270. doi: 10.1007/s00277-022-04932-6. Epub 2022 Aug 23. Ann Hematol. 2022. PMID: 35997804 Free PMC article.
71 results